Phosphoproteomics-directed Manipulation Reveals SEC22B As a Hepatocellular Signaling Node Governing Metabolic Actions of Glucagon
Overview
Authors
Affiliations
The peptide hormone glucagon is a fundamental metabolic regulator that is also being considered as a pharmacotherapeutic option for obesity and type 2 diabetes. Despite this, we know very little regarding how glucagon exerts its pleiotropic metabolic actions. Given that the liver is a chief site of action, we performed in situ time-resolved liver phosphoproteomics to reveal glucagon signaling nodes. Through pathway analysis of the thousands of phosphopeptides identified, we reveal "membrane trafficking" as a dominant signature with the vesicle trafficking protein SEC22 Homolog B (SEC22B) S137 phosphorylation being a top hit. Hepatocyte-specific loss- and gain-of-function experiments reveal that SEC22B was a key regulator of glycogen, lipid and amino acid metabolism, with SEC22B-S137 phosphorylation playing a major role in glucagon action. Mechanistically, we identify several protein binding partners of SEC22B affected by glucagon, some of which were differentially enriched with SEC22B-S137 phosphorylation. In summary, we demonstrate that phosphorylation of SEC22B is a hepatocellular signaling node mediating the metabolic actions of glucagon and provide a rich resource for future investigations on the biology of glucagon action.
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes.
Wu Y, Chan A, Hauke J, Htin Aung O, Foollee A, Cleofe M Mol Metab. 2024; 90:102064.
PMID: 39536823 PMC: 11617456. DOI: 10.1016/j.molmet.2024.102064.